Carmustine Other names: Bischlorethylnitrosourea Bischlorethylnitrosurea BCNU

Chemical formula: C₅H₉Cl₂N₃O₂  Molecular mass: 214.05 g/mol  PubChem compound: 2578

Therapeutic indications

Carmustine is indicated for:

Glioblastoma, brain-stem gliomas, medulloblastoma, astrocytoma, ependymoma, brain metastases

Population group: only adults (18 years old or older)

Carmustine is effective in brain tumours (glioblastoma, Brain-stem gliomas, medulloblastoma, astrocytoma and ependymoma), brain metastases as a single agent or in combination with other antineoplastic agents and/or other therapeutic measures (radiotherapy, surgery).

For this indication, competent medicine agencies globally authorize below treatments (click for details):

Non-Hodgkin's lymphoma, Hodgkin's disease

Population group: only adults (18 years old or older)

Carmustine is effective in secondary therapy in non-Hodgkin’s lymphoma and Hodgkin’s disease as a single agent or in combination with other antineoplastic agents and/or other therapeutic measures (radiotherapy, surgery).

For this indication, competent medicine agencies globally authorize below treatments (click for details):

Contraindications

Carmustine is contraindicated in the following cases:

Lactation

Lactation

Severe bone marrow depression

Bone marrow depression

Severe (end-stage) renal impairment

Renal failure stage 5: Kidney failure (GFR <15 mL/min/1.73 m2 or dialysis)

Get recommendations

Factors such as age, gender, and health history are evaluated to create a personalized medication regimen.

Ask the Reasoner

Related medicines

© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.